Health & bio
Neomorph's $100M Series B Funds NEO-811 Clinical Advancement
The $100 million Series B accelerates NEO-811's Phase 1/2 trials in renal cell carcinoma, setting the stage for near-term readouts.
Primary sources · 1
The $100 million Series B accelerates NEO-811's Phase 1/2 trials in renal cell carcinoma, setting the stage for near-term readouts.
7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.